Skip to content
  • Company
  • ECGenius™ System
  • CARDIALYTICS™
  • Science
  • News
  • Contact
Menu
  • Company
  • ECGenius™ System
  • CARDIALYTICS™
  • Science
  • News
  • Contact

Progressing Clinical Evidence: CathVision Announces First Patient Enrolled In Persistent AF Study at OLV Hospital Aalst

CathVision announces initial patient enrollment of a follow-on clinical study to demonstrate the value of the Signal Complexity algorithm at OLV Hospital Aalst in Belgium led by Dr. Tom De Potter.

CathVision ApS
Connect With Us

European Office (HQ)
Lygten 37 st. th.
2400 Copenhagen NV 
DENMARK

+45 31 47 07 30

US Office
12800 Whitewater Dr #100
Minnetonka, MN 55343
USA

Linkedin Twitter

contact@cathvision.com

ECGenius™ System,  Signal Complexity™,  and PVI Analyzer™ are FDA cleared. ECGenius™ System, Signal Complexity™, and PVI Analyzer™ are not approved for sale in the EU.

Fast Mapping™ is not FDA cleared or approved for sale in the EU.  

This product has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 872902 – CathVision Cube.

Support Contact

For technical support, please write to support@cathvision.com.
For all other inquiries related to CathVision products and services, please write to contact@cathvision.com.
Response within 24 hours on weekdays.

Privacy Policy

Terms and Conditions

© 2024 CathVision. All rights reserved.